Research-grade peptide intelligence, delivered every Tuesday. Deep analysis, study breakdowns, and regulatory updates.
Every Tuesday: one landmark study, one protocol, one regulatory update. Plus new research posts as they publish. Free.
Retatrutide hits 30.3% weight loss at two years. Thymosin Alpha-1 fails Phase 3. Kisspeptin goes nasal. FDA PCAC July agenda confirmed.
Survodutide Phase 2 MASH data, why the second receptor matters, and the complete 12-peptide FDA list from April 15.
Orforglipron FDA approved. Seven peptides going to advisory panel in July. Here is what both announcements actually mean.
CagriSema Phase 3 results, retatrutide TRIUMPH-4, SS-31 FDA approval, and what the Category 2 reclassification actually means.